Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Dorinsky

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Pulmonary Pharmacology & Therapeutics|March 17, 2018
The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adultsPatrick Darken, Paolo DePetrillo, Colin Reisner, et al.
Clinical Therapeutics|April 8, 2020
Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy AdultsPaul Dorinsky, Paolo DePetrillo, Kiernan DeAngelis, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 7, 2002
Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of agePeter Creticos, Katharine Knobil, Lisa D Edwards, et al.
Respiratory Research|July 31, 2019
Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized studyEdward M Kerwin, Gary T Ferguson, Mindy Mo, et al.
Pulmonary Pharmacology & Therapeutics|November 5, 2020
Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjectsYing Huang, Pryseley Nkouibert Assam, Cong Feng, et al.
Respiratory Medicine|December 14, 2004
The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthmaJacqueline R Carranza Rosenzweig, Lisa Edwards, William Lincourt, et al.
Allergy and Asthma Proceedings|July 25, 2018
Randomized dose-ranging study of a budesonide metered-dose inhaler by using co-suspension delivery technology in asthmaS David Miller, Jack Nyberg, Shahid Siddiqui, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 13, 2005
The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthmaRandolph Malone, Craig LaForce, Sai Nimmagadda, et al.
Pulmonary Pharmacology & Therapeutics|December 17, 2019
Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPDLeonard J Dunn, Edward M Kerwin, Kiernan DeAngelis, et al.
Clinical Therapeutics|February 24, 2006
Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week studyRobert A Nathan, Anthony Rooklin, Lynne Schoaf, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Pulmonary Pharmacology & Therapeutics|March 17, 2018
The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adultsPatrick Darken, Paolo DePetrillo, Colin Reisner, et al.
Clinical Therapeutics|April 8, 2020
Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy AdultsPaul Dorinsky, Paolo DePetrillo, Kiernan DeAngelis, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 7, 2002
Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of agePeter Creticos, Katharine Knobil, Lisa D Edwards, et al.
Respiratory Research|July 31, 2019
Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized studyEdward M Kerwin, Gary T Ferguson, Mindy Mo, et al.
Pulmonary Pharmacology & Therapeutics|November 5, 2020
Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjectsYing Huang, Pryseley Nkouibert Assam, Cong Feng, et al.
Respiratory Medicine|December 14, 2004
The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthmaJacqueline R Carranza Rosenzweig, Lisa Edwards, William Lincourt, et al.
Allergy and Asthma Proceedings|July 25, 2018
Randomized dose-ranging study of a budesonide metered-dose inhaler by using co-suspension delivery technology in asthmaS David Miller, Jack Nyberg, Shahid Siddiqui, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 13, 2005
The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthmaRandolph Malone, Craig LaForce, Sai Nimmagadda, et al.
Pulmonary Pharmacology & Therapeutics|December 17, 2019
Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPDLeonard J Dunn, Edward M Kerwin, Kiernan DeAngelis, et al.
Clinical Therapeutics|February 24, 2006
Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week studyRobert A Nathan, Anthony Rooklin, Lynne Schoaf, et al.
Pageof 6